Medconn Diagnostics, established in 1992, is a leading company specializing in the research and development, manufacturing, sales, and service of in vitro diagnostic (IVD) products. Headquartered in Hangzhou, China, Medconn Diagnostics serves a broad market across most provinces and regions in China, offering a comprehensive range of products, including HbA1c (HPLC) testing, Hematology, CLIA, Cardiovascular rapid tests,Biochemistry, etc. 

In 2019, we revitalized the Medconn Diagnostics brand, focusing on integrating and enhancing our product portfolio while elevating our R&D capabilities and service quality. he Medconn Diagnostics group comprises 5 companies: Hangzhou Medconn Diagnostics Technology Co., Ltd., Shanghai Medconn Medical Technology Co., Ltd., Shanghai Medconn Biotechnology Co., Ltd., Beijing Medconn Medical Devices Co., Ltd., and Medconn Diagnostics Technology (HK) Ltd.  Among them, Hangzhou Medconn Diagnostics Technology Co., Ltd. serves as the headquarter, managing unified external sales and service, while the other four branches are dedicated to business operations. 

The Medconn Diagnostics Industrial Park, located in Jinshan District, Shanghai, spans nearly 40,000 square meters and serves as a hub for R&D, production, and logistics. As of 2019, our R&D system has secured 9 invention patents, 59 utility model patents, 6 design patents, 7 software copyrights, and 12 Certificates of Transformation of High-tech Achievements. Our production facilities are certified by ISO9001 and ISO13485, featuring 10,000-grade purification workshops and 9,500 square meters of clean rooms.CE certificate for all of our products is compulsroy, and some products is approved by FDA or accredidated by IFCC, NGSP, NMPA, etc. 

Looking ahead, Medconn Diagnostics remains committed to our customer-centric business philosophy. We will continue to enhance our product and service quality through ongoing technological and service innovations, contributing to the robust growth of the in vitro diagnostics (IVD) industry in China.